A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/00 (2006.01) A61K 31/138 (2006.01) A61K 31/56 (2006.01) A61K 31/57 (2006.01) A61K 31/70 (2006.01) A61K 38/17 (2006.01) A61K 38/19 (2006.01) A61K 39/395 (2006.01) C07K 16/24 (2006.01)
Patent
CA 2191070
Disclosed are: a composition for use in the treatment of endometriosis, comprising an agent capable of interfering with the production and/or activity of VEGF, and a physiologically acceptable carrier substance; a composition for the treatment of endometriosis comprising an agent which inhibits the activation and/or recruitment of peritoneal macrophages, and a physiologically acceptable carrier, and methods of making the compositions and their use in the treatment of endometriosis.
On décrit une composition utile dans le traitement de l'endométriose, comprenant un agent susceptible de contrecarrer la production et/ou l'activité du facteur de croissance des cellules endothéliales, ainsi qu'un excipient acceptable sur le plan physiologique; on décrit également une composition destinée au traitement de l'endométriose comprenant un agent inhibant l'activation et/ou la mobilisation des macrophages péritonéaux, ainsi qu'un excipient acceptable sur le plan physiologique; on décrit encore des procédés de fabrication de ces compositions ainsi que l'utilisation de celles-ci dans le traitement de l'endométriose.
Charnock-Jones David Stephen
Mclaren John
Prentice Andrew
Smith Stephen Kevin
Kirby Eades Gale Baker
Metris Therapeutics Limited
LandOfFree
Use of anti-vegf agents in the treatment of endometriosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of anti-vegf agents in the treatment of endometriosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of anti-vegf agents in the treatment of endometriosis will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1581785